Homology model and docking-based virtual screening for ligands of human dyskerin as new inhibitors of telomerase for cancer treatment
- Autores
- Armando, Romina Gabriela; Mengual Gómez, Diego Luis; Juritz, Ezequiel Ivan; Lorenzano Menna, Pablo; Gomez, Daniel Eduardo
- Año de publicación
- 2018
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Immortality is one of the main features of cancer cells. Tumor cells have an unlimited replicative potential, principally due to the holoenzyme telomerase. Telomerase is composed mainly by dyskerin (DKC1), a catalytic retrotranscriptase (hTERT) and an RNA template (hTR). The aim of this work is to develop new inhibitors of telomerase, selecting the interaction between hTR–DKC1 as a target. We designed two models of the human protein DKC1: homology and ab initio. These models were evaluated by different procedures, revealing that the homology model parameters were the most accurate. We selected two hydrophobic pockets contained in the PUA (pseudouridine synthase and archaeosine transglycosylase) domain, using structural and stability analysis. We carried out a docking-based virtual screen on these pockets, using the reported mutation K314 as the center of the docking. The hDKC1 model was tested against a library of 450,000 drug-like molecules. We selected the first 10 molecules that showed the highest affinity values to test their inhibitory activity on the cell line MDA MB 231 (Monroe Dunaway Anderson Metastasis Breast cancer 231), obtaining three compounds that showed inhibitory effect. These results allowed us to validate our design and set the basis to continue with the study of telomerase inhibitors for cancer treatment.
Fil: Armando, Romina Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina
Fil: Mengual Gómez, Diego Luis. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Juritz, Ezequiel Ivan. Universidad Andrés Bello; Chile
Fil: Lorenzano Menna, Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología; Argentina
Fil: Gomez, Daniel Eduardo. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina - Materia
-
CANCER
DKC1
HTR
INHIBITORS
TELOMERASE - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by/2.5/ar/
- Repositorio
.jpg)
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/98541
Ver los metadatos del registro completo
| id |
CONICETDig_fdf0630c7afe2e8dc26271c636a0d795 |
|---|---|
| oai_identifier_str |
oai:ri.conicet.gov.ar:11336/98541 |
| network_acronym_str |
CONICETDig |
| repository_id_str |
3498 |
| network_name_str |
CONICET Digital (CONICET) |
| spelling |
Homology model and docking-based virtual screening for ligands of human dyskerin as new inhibitors of telomerase for cancer treatmentArmando, Romina GabrielaMengual Gómez, Diego LuisJuritz, Ezequiel IvanLorenzano Menna, PabloGomez, Daniel EduardoCANCERDKC1HTRINHIBITORSTELOMERASEhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Immortality is one of the main features of cancer cells. Tumor cells have an unlimited replicative potential, principally due to the holoenzyme telomerase. Telomerase is composed mainly by dyskerin (DKC1), a catalytic retrotranscriptase (hTERT) and an RNA template (hTR). The aim of this work is to develop new inhibitors of telomerase, selecting the interaction between hTR–DKC1 as a target. We designed two models of the human protein DKC1: homology and ab initio. These models were evaluated by different procedures, revealing that the homology model parameters were the most accurate. We selected two hydrophobic pockets contained in the PUA (pseudouridine synthase and archaeosine transglycosylase) domain, using structural and stability analysis. We carried out a docking-based virtual screen on these pockets, using the reported mutation K314 as the center of the docking. The hDKC1 model was tested against a library of 450,000 drug-like molecules. We selected the first 10 molecules that showed the highest affinity values to test their inhibitory activity on the cell line MDA MB 231 (Monroe Dunaway Anderson Metastasis Breast cancer 231), obtaining three compounds that showed inhibitory effect. These results allowed us to validate our design and set the basis to continue with the study of telomerase inhibitors for cancer treatment.Fil: Armando, Romina Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; ArgentinaFil: Mengual Gómez, Diego Luis. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Juritz, Ezequiel Ivan. Universidad Andrés Bello; ChileFil: Lorenzano Menna, Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología; ArgentinaFil: Gomez, Daniel Eduardo. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaMolecular Diversity Preservation International2018-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/98541Armando, Romina Gabriela; Mengual Gómez, Diego Luis; Juritz, Ezequiel Ivan; Lorenzano Menna, Pablo; Gomez, Daniel Eduardo; Homology model and docking-based virtual screening for ligands of human dyskerin as new inhibitors of telomerase for cancer treatment; Molecular Diversity Preservation International; International Journal of Molecular Sciences; 19; 10; 10-2018; 1-161422-0067CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/1422-0067/19/10/3216info:eu-repo/semantics/altIdentifier/doi/10.3390/ijms19103216info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2026-08-25T14:49:41Zoai:ri.conicet.gov.ar:11336/98541instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982026-08-25 14:49:41.591CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
| dc.title.none.fl_str_mv |
Homology model and docking-based virtual screening for ligands of human dyskerin as new inhibitors of telomerase for cancer treatment |
| title |
Homology model and docking-based virtual screening for ligands of human dyskerin as new inhibitors of telomerase for cancer treatment |
| spellingShingle |
Homology model and docking-based virtual screening for ligands of human dyskerin as new inhibitors of telomerase for cancer treatment Armando, Romina Gabriela CANCER DKC1 HTR INHIBITORS TELOMERASE |
| title_short |
Homology model and docking-based virtual screening for ligands of human dyskerin as new inhibitors of telomerase for cancer treatment |
| title_full |
Homology model and docking-based virtual screening for ligands of human dyskerin as new inhibitors of telomerase for cancer treatment |
| title_fullStr |
Homology model and docking-based virtual screening for ligands of human dyskerin as new inhibitors of telomerase for cancer treatment |
| title_full_unstemmed |
Homology model and docking-based virtual screening for ligands of human dyskerin as new inhibitors of telomerase for cancer treatment |
| title_sort |
Homology model and docking-based virtual screening for ligands of human dyskerin as new inhibitors of telomerase for cancer treatment |
| dc.creator.none.fl_str_mv |
Armando, Romina Gabriela Mengual Gómez, Diego Luis Juritz, Ezequiel Ivan Lorenzano Menna, Pablo Gomez, Daniel Eduardo |
| author |
Armando, Romina Gabriela |
| author_facet |
Armando, Romina Gabriela Mengual Gómez, Diego Luis Juritz, Ezequiel Ivan Lorenzano Menna, Pablo Gomez, Daniel Eduardo |
| author_role |
author |
| author2 |
Mengual Gómez, Diego Luis Juritz, Ezequiel Ivan Lorenzano Menna, Pablo Gomez, Daniel Eduardo |
| author2_role |
author author author author |
| dc.subject.none.fl_str_mv |
CANCER DKC1 HTR INHIBITORS TELOMERASE |
| topic |
CANCER DKC1 HTR INHIBITORS TELOMERASE |
| purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.2 https://purl.org/becyt/ford/3 |
| dc.description.none.fl_txt_mv |
Immortality is one of the main features of cancer cells. Tumor cells have an unlimited replicative potential, principally due to the holoenzyme telomerase. Telomerase is composed mainly by dyskerin (DKC1), a catalytic retrotranscriptase (hTERT) and an RNA template (hTR). The aim of this work is to develop new inhibitors of telomerase, selecting the interaction between hTR–DKC1 as a target. We designed two models of the human protein DKC1: homology and ab initio. These models were evaluated by different procedures, revealing that the homology model parameters were the most accurate. We selected two hydrophobic pockets contained in the PUA (pseudouridine synthase and archaeosine transglycosylase) domain, using structural and stability analysis. We carried out a docking-based virtual screen on these pockets, using the reported mutation K314 as the center of the docking. The hDKC1 model was tested against a library of 450,000 drug-like molecules. We selected the first 10 molecules that showed the highest affinity values to test their inhibitory activity on the cell line MDA MB 231 (Monroe Dunaway Anderson Metastasis Breast cancer 231), obtaining three compounds that showed inhibitory effect. These results allowed us to validate our design and set the basis to continue with the study of telomerase inhibitors for cancer treatment. Fil: Armando, Romina Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina Fil: Mengual Gómez, Diego Luis. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Juritz, Ezequiel Ivan. Universidad Andrés Bello; Chile Fil: Lorenzano Menna, Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología; Argentina Fil: Gomez, Daniel Eduardo. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina |
| description |
Immortality is one of the main features of cancer cells. Tumor cells have an unlimited replicative potential, principally due to the holoenzyme telomerase. Telomerase is composed mainly by dyskerin (DKC1), a catalytic retrotranscriptase (hTERT) and an RNA template (hTR). The aim of this work is to develop new inhibitors of telomerase, selecting the interaction between hTR–DKC1 as a target. We designed two models of the human protein DKC1: homology and ab initio. These models were evaluated by different procedures, revealing that the homology model parameters were the most accurate. We selected two hydrophobic pockets contained in the PUA (pseudouridine synthase and archaeosine transglycosylase) domain, using structural and stability analysis. We carried out a docking-based virtual screen on these pockets, using the reported mutation K314 as the center of the docking. The hDKC1 model was tested against a library of 450,000 drug-like molecules. We selected the first 10 molecules that showed the highest affinity values to test their inhibitory activity on the cell line MDA MB 231 (Monroe Dunaway Anderson Metastasis Breast cancer 231), obtaining three compounds that showed inhibitory effect. These results allowed us to validate our design and set the basis to continue with the study of telomerase inhibitors for cancer treatment. |
| publishDate |
2018 |
| dc.date.none.fl_str_mv |
2018-10 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/98541 Armando, Romina Gabriela; Mengual Gómez, Diego Luis; Juritz, Ezequiel Ivan; Lorenzano Menna, Pablo; Gomez, Daniel Eduardo; Homology model and docking-based virtual screening for ligands of human dyskerin as new inhibitors of telomerase for cancer treatment; Molecular Diversity Preservation International; International Journal of Molecular Sciences; 19; 10; 10-2018; 1-16 1422-0067 CONICET Digital CONICET |
| url |
http://hdl.handle.net/11336/98541 |
| identifier_str_mv |
Armando, Romina Gabriela; Mengual Gómez, Diego Luis; Juritz, Ezequiel Ivan; Lorenzano Menna, Pablo; Gomez, Daniel Eduardo; Homology model and docking-based virtual screening for ligands of human dyskerin as new inhibitors of telomerase for cancer treatment; Molecular Diversity Preservation International; International Journal of Molecular Sciences; 19; 10; 10-2018; 1-16 1422-0067 CONICET Digital CONICET |
| dc.language.none.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/1422-0067/19/10/3216 info:eu-repo/semantics/altIdentifier/doi/10.3390/ijms19103216 |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by/2.5/ar/ |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
https://creativecommons.org/licenses/by/2.5/ar/ |
| dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf application/pdf |
| dc.publisher.none.fl_str_mv |
Molecular Diversity Preservation International |
| publisher.none.fl_str_mv |
Molecular Diversity Preservation International |
| dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
| reponame_str |
CONICET Digital (CONICET) |
| collection |
CONICET Digital (CONICET) |
| instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
| _version_ |
1874774735244492800 |
| score |
13.334379 |